Febuxostat ameliorates diabetic renal injury in a streptozotocin-induced diabetic rat model

American Journal of Nephrology

Volumn 40, Issue 1, 2014, Pages 56-63

  Lee, Hong Joo ^a   Jeong, Kyung Hwan ^b   Kim, Yang Gyun ^b   Moon, Joo Young ^b   Lee, Sang Ho ^b   Ihm, Chun Gyoo ^b   Sung, Ji Youn ^b   Lee, Tae Won ^b  

^a Seoul Red Cross Hospital   (South Korea)

^b Kyung Hee University Hospital   (South Korea)

Author keywords

Diabetic renal injury; Febuxostat; Xanthine oxidase inhibitor

Indexed keywords

3 NITROTYROSINE; 8 HYDROXYDEOXYGUANOSINE; BIOCHEMICAL MARKER; CYCLOOXYGENASE 2; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; FEBUXOSTAT; GLUCOSE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN ED 1; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1; XANTHINE DEHYDROGENASE; XANTHINE OXIDASE; 8-OXO-7-HYDRODEOXYGUANOSINE; ANTIGOUT AGENT; ANTINEOPLASTIC ANTIBIOTIC; DEOXYGUANOSINE; ECTODYSPLASIN A; MESSENGER RNA; PTGS2 PROTEIN, RAT; STREPTOZOCIN; THIAZOLE DERIVATIVE; PEPTIDES AND PROTEINS;

ALBUMINURIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME INHIBITION; GENE EXPRESSION; GLOMERULUS; GLUCOSE BLOOD LEVEL; INFLAMMATION; KIDNEY CORTEX; KIDNEY INJURY; KIDNEY MASS; KIDNEY PARENCHYMA; KIDNEY TUBULE; MALE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RAT; RENAL PROTECTION; STREPTOZOTOCIN-INDUCED DIABETES MELLITUS; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; DRUG EFFECTS; EXPERIMENTAL DIABETES MELLITUS; KIDNEY; LIVER; METABOLISM; SPRAGUE DAWLEY RAT; URINE; BODY WEIGHT; DRUG EFFECT; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1 GENE; GENE; URINALYSIS; VASCULAR CELL ADHESION MOLECULE 1 GENE;

ALBUMINURIA; ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; CYCLOOXYGENASE 2; DEOXYGUANOSINE; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEPHROPATHIES; ECTODYSPLASINS; FEBUXOSTAT; GOUT SUPPRESSANTS; KIDNEY; LIVER; MALE; NF-KAPPA B; OXIDATIVE STRESS; RATS; RATS, SPRAGUE-DAWLEY; RNA, MESSENGER; STREPTOZOCIN; THIAZOLES; XANTHINE DEHYDROGENASE; XANTHINE OXIDASE;

EID: 84904270853     PISSN: 02508095     EISSN: 14219670     Source Type: Journal    
DOI: 10.1159/000363421     Document Type: Article

References (34)

1. Caramori ML, Mauer M: Diabetes and nephropathy. Curr Opin Nephrol Hypertens 2003; 12: 273-282
2. Andersen AR, Christiansen JS, Andersen JK, Kreiner S, Deckert T: Diabetic nephropathy in type 1 (insulin-dependent) diabetes: An epidemiological study. Diabetologia 1983; 25: 496-501
3. Krolewski AS, Warram JH, Christlieb AR, Busick EJ, Kahn CR: The changing natural history of nephropathy in type 1 diabetes. Am J Med 1985; 78: 785-794
4. Rossing P, Rossing K, Jacobsen P, Parving HH: Unchanged incidence of diabetic nephropathy in IDDM patients. Diabetes 1995; 44: 739-743
5. Coughlan MT, Mibus AL, Forbes JM: Oxidative stress and advanced glycation in diabetic nephropathy. Ann NY Acad Sci 2008; 1126: 190-193
6. Baynes JW, Thorpe SR: Role of oxidative stress in diabetic complications: A new perspective on an old paradigm. Diabetes 1999; 48: 1-9
7. Cameron NE, Cotter MA: Effects of antioxidants on nerve and vascular dysfunction in experimental diabetes. Diabetes Res Clin Pract 1999; 45: 137-146
8. Mima A: Inflammation and oxidative stress in diabetic nephropathy: New insights on its inhibition as new therapeutic targets. J Diabetes Res 2013; 2013: 248563
9. Becker MA, Schumacher HR Jr, Wortmann RL, MacDonald PA, Eustace D, Palo WA, Streit J, Joseph-Ridge N: Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med 2005; 353: 2450-2461
10. Yu KH: Febuxostat: A novel non-purine selective inhibitor of xanthine oxidase for the treatment of hyperuricemia in gout. Recent Pat Inflamm Allergy Drug Discov 2007; 1: 69-75
11. Okamoto K, Eger BT, Nishino T, Kondo S, Pai EF: An extremely potent inhibitor of xanthine oxidoreductase. Crystal structure of the enzyme-inhibitor complex and mechanism of inhibition. J Biol Chem 2003; 278: 1848-1855
12. Saban-Ruiz J, Alonso-Pacho A, Fabregate-Fuente M, De La Puerta Gonzalez-Quevedo C: Xanthine oxidase inhibitor febuxostat as a novel agent postulated to act against vascular inflammation. Antiinflamm Antiallergy Agents Med Chem 2013; 12: 94-99
13. Sanchez-Lozada LG, Tapia E, Soto V, Avila-Casado C, Franco M, Wessale JL, Zhao L, Johnson RJ: Effect of febuxostat on the progression of renal disease in 5/6 nephrectomy rats with and without hyperuricemia. Nephron Physiol 2008; 108:p69-p78
14. Tsuda H, Kawada N, Kaimori JY, Kitamura H, Moriyama T, Rakugi H, Takahara S, Isaka Y: Febuxostat suppressed renal ischemia-reperfusion injury via reduced oxidative stress. Biochem Biophys Res Commun 2012; 427: 266-272
15. Omori H, Kawada N, Inoue K, Ueda Y, Yamamoto R, Matsui I, Kaimori J, Takabatake Y, Moriyama T, Isaka Y, Rakugi H: Use of xanthine oxidase inhibitor febuxostat inhibits renal interstitial inflammation and fibrosis in unilateral ureteral obstructive nephropathy. Clin Exp Nephrol 2012; 16: 549-556
16. Sanchez-Lozada LG, Tapia E, Bautista-Garcia P, Soto V, Avila-Casado C, Vega-Campos IP, Nakagawa T, Zhao L, Franco M, Johnson RJ: Effects of febuxostat on metabolic and renal alterations in rats with fructose-induced metabolic syndrome. Am J Physiol Renal Physiol 2008; 294:F710-F718
17. Balakumar P, Chakkarwar VA, Singh M: Ameliorative effect of combination of benfotiamine and fenofibrate in diabetes-induced vascular endothelial dysfunction and nephropathy in the rat. Mol Cell Biochem 2009; 320: 149-162
18. Giacco F, Brownlee M: Oxidative stress and diabetic complications. Circ Res 2010; 107: 1058-1070
19. Zhang Y, Wada J, Hashimoto I, Eguchi J, Yasuhara A, Kanwar YS, Shikata K, Makino H: Therapeutic approach for diabetic nephropathy using gene delivery of translocase of inner mitochondrial membrane 44 by reducing mitochondrial superoxide production. J Am Soc Nephrol 2006; 17: 1090-1101
20. DeRubertis FR, Craven PA, Melhem MF: Acceleration of diabetic renal injury in the superoxide dismutase knockout mouse: Effects of tempol. Metabolism 2007; 56: 1256-1264
21. Agarwal R: Anti-inflammatory effects of short-Term pioglitazone therapy in men with advanced diabetic nephropathy. Am J Physiol Renal Physiol 2006; 290:F600-F605
22. Keel CE, Wang Z, Colli J, Grossman L, Majid D, Lee BR: Protective effects of reducing renal ischemia-reperfusion injury during renal hilar clamping: Use of allopurinol as a nephroprotective agent. Urology 2013; 81: 210.e5-e10
23. Goicoechea M, De Vinuesa SG, Verdalles U, Ruiz-Caro C, Ampuero J, Rincon A, Arroyo D, Luno J: Effect of allopurinol in chronic kidney disease progression and cardiovascular risk. Clin J Am Soc Nephrol 2010; 5: 1388-1393
24. Sautin YY, Nakagawa T, Zharikov S, Johnson RJ: Adverse effects of the classic antioxidant uric acid in adipocytes: NADPH oxidase-mediated oxidative/nitrosative stress. Am J Physiol Cell Physiol 2007; 293:C584-C596
25. Kawada N, Moriyama T, Ando A, Fukunaga M, Miyata T, Kurokawa K, Imai E, Hori M: Increased oxidative stress in mouse kidneys with unilateral ureteral obstruction. Kidney Int 1999; 56: 1004-1013
26. Yu MA, Sanchez-Lozada LG, Johnson RJ, Kang DH: Oxidative stress with an activation of the renin-Angiotensin system in human vascular endothelial cells as a novel mechanism of uric acid-induced endothelial dysfunction. J Hypertens 2010; 28: 1234-1242
27. Vanholder R, Patel S, Hsu CH: Effect of uric acid on plasma levels of 1,25(OH) 2 D in renal failure. J Am Soc Nephrol 1993; 4: 1035-1038
28. Heidland A, Sebekova K, Schinzel R: Advanced glycation end products and the progressive course of renal disease. Am J Kidney Dis 2001; 38:S100-S106
29. Elmarakby AA, SulliVan JC: Relationship between oxidative stress and inflammatory cytokines in diabetic nephropathy. Cardiovasc Ther 2012; 30: 49-59
30. Coward RJ, Welsh GI, Koziell A, Hussain S, Lennon R, Ni L, Tavare JM, Mathieson PW, Saleem MA: Nephrin is critical for the action of insulin on human glomerular podocytes. Diabetes 2007; 56: 1127-1135
31. Wolf G, Chen S, Ziyadeh FN: From the periphery of the glomerular capillary wall toward the center of disease: Podocyte injury comes of age in diabetic nephropathy. Diabetes 2005; 54: 1626-1634
32. Russo LM, Sandoval RM, Campos SB, Molitoris BA, Comper WD, Brown D: Impaired tubular uptake explains albuminuria in early diabetic nephropathy. J Am Soc Nephrol 2009; 20: 489-494
33. Tomlinson KC, Gardiner SM, Hebden RA, Bennett T: Functional consequences of streptozotocin-induced diabetes mellitus, with particular reference to the cardiovascular system. Pharmacol Rev 1992; 44: 103-150
34. Tesch GH, Allen TJ: Rodent models of streptozotocin-induced diabetic nephropathy. Nephrology (Carlton) 2007; 12: 261-266